Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
193.62
+0.68 (+0.35%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about AbbVie
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
60
61
Next >
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
April 09, 2024
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
Via
The Motley Fool
3 No-Brainer Dividend Stocks to Buy in April
April 06, 2024
Income investors will find a lot to like about these stocks.
Via
The Motley Fool
AbbVie Unusual Options Activity For April 05
April 05, 2024
Via
Benzinga
Smart Money Is Betting Big In ABBV Options
April 04, 2024
Via
Benzinga
Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year
April 04, 2024
These seven dividend stocks provide a base for $50,000 in income per year for dedicated investors with patience.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
April 03, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
March 27, 2024
Via
Benzinga
Assessing AbbVie's Performance Against Competitors In Biotechnology Industry
March 26, 2024
Via
Benzinga
The Latest Analyst Ratings For AbbVie
March 22, 2024
Via
Benzinga
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
April 03, 2024
FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements...
Via
Benzinga
The 3 Best Stocks to Buy in April 2024
April 02, 2024
With market dynamics shifting in the wind, concerned investors may want to target these ideas for best stocks to buy in April.
Via
InvestorPlace
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
April 02, 2024
The company hopes to treat noninfectious uveitis and is rivaling AbbVie's Humira.
Via
Investor's Business Daily
Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation
April 02, 2024
These stocks can deliver powerhouse portfolio growth in the years ahead.
Via
The Motley Fool
Meet The "Magnificent Seven" of Healthcare Stocks
April 01, 2024
The tech sector doesn't have a monopoly on magnificent corporations.
Via
The Motley Fool
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
March 30, 2024
These advantaged businesses have what it takes to keep raising their payouts.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
March 28, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Long Live the Dividend Kings: 3 Top Picks to Build an Income Portfolio
March 28, 2024
The dividend kings are excellent stocks with which to establish an income portfolio with these three dividend king stocks standing out.
Via
InvestorPlace
Tuesday Talk: Big-Tech Under Attack
March 26, 2024
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.
Via
Talk Markets
Biotechnology And Healthcare, A Bit Of A Lull
March 25, 2024
Strong momentum of Tech and Chip stocks may be too good of a distraction for biotech investors.
Via
Talk Markets
Nasdaq Turns Higher; Akanda Shares Plunge
March 25, 2024
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
March 25, 2024
Landos Biopharma stock is up on Monday as LABP investors learn about a massive acquisition deal with AbbVie that values it at $137.5 million.
Via
InvestorPlace
Crude Oil Moves Higher; US New Home Sales Fall In February
March 25, 2024
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
March 25, 2024
AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease.
Via
Benzinga
US Stocks Down; Chicago Fed National Activity Index Rises In February
March 25, 2024
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
March 21, 2024
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
Via
Talk Markets
Healthcare And Biotech Update With Market At 2024 Highs
March 20, 2024
The bull market is intact with technology Stocks dominating, but XLV is up 6.89%YTD.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 18, 2024
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
60
61
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.